MARKET

AWH

AWH

Aspira Womens Health Inc
NASDAQ
1.480
-0.010
-0.67%
After Hours: 1.530 +0.05 +3.38% 16:08 07/19 EDT
OPEN
1.470
PREV CLOSE
1.490
HIGH
1.536
LOW
1.410
VOLUME
40.58K
TURNOVER
0
52 WEEK HIGH
6.75
52 WEEK LOW
0.8600
MARKET CAP
18.43M
P/E (TTM)
-1.0246
1D
5D
1M
3M
1Y
5Y
1D
Aspira Women's Health Inc Files For Offering Of Up To 2.5M Shares By The Selling Stockholders
Benzinga · 2d ago
Aspira Women's Health files to sell 2.5M shares of common stock for holders
Aspira Women's Health files to sell 2.5M shares of common stock for holders. This preliminary prospectus is not an offer to sell. The company filed a prospectus related to the offer and sale of 2.4 million shares of stock in 2024.
Seeking Alpha · 2d ago
ASPIRA WOMEN'S HEALTH INC FILES FOR OFFERING OF UP TO 2.5 MLN SHARES BY THE SELLING STOCKHOLDERS - SEC FILING
Reuters · 2d ago
Weekly Report: what happened at AWH last week (0708-0712)?
Weekly Report · 4d ago
Aspira Women's Health reports Q2 OvaSuite product volume
Aspira Women's Health reports Q2 OvaSuite product volume grew 11% over the prior quarter. Preliminary OvaWatch volume grew 24% in Q2 over the previous quarter to 1,307 units. The company added that Ova Suite volume during Q2 grew 11%.
Seeking Alpha · 07/11 14:23
Aspira Women's Health Announces Preliminary OvaWatch Volume During Q2 2024 Grew 24% QoQ To 1,307 Units; Preliminary OvaSuite Volume During Q2 2024 Grew 11% QoQ To 6,471 Units
Aspira Women's Health Inc. Announces preliminary second quarter 2024 OvaSuite product volume and highlights. Preliminary OvaWatch volume during Q2 2024 grew 24% over the prior quarter to 1,307 units. The Company has been selected as a finalist for an ARPA-H grant to develop a blood test for endometriosis.
Benzinga · 07/11 12:24
Press Release: Aspira Women's Health Announces Closing of $1.9 Million Private Placement Equity Financing
Dow Jones · 07/09 16:12
Weekly Report: what happened at AWH last week (0701-0705)?
Weekly Report · 07/08 12:03
More
About AWH
Aspira Women's Health Inc. is engaged in the discovery, development, and commercialization of noninvasive, artificial intelligence (AI)-powered tests to aid in the diagnosis of gynecologic diseases. The Company's portfolio includes OvaWatch and the Ova1Plus workflow, offered to clinicians as OvaSuite. OvaWatch is used to assess ovarian cancer risk for women with an adnexal mass where their initial clinical assessment indicates the mass is indeterminate or benign. The Ova1Plus workflow is designed to assess the risk of ovarian malignancy in women planning for surgery and uses two tests, Ova1 as the primary test and Overa as a reflex for Ova1 intermediate range results. Its in-development test pipeline includes OvaMDxSM risk assessment, EndoCheck and EndoMDx, which are designed to expand its ovarian cancer portfolio and address the tremendous need for noninvasive diagnostics for endometriosis. EndoCheck is a noninvasive test designed to identify endometriomas.

Webull offers Aspira Women's Health Inc stock information, including NASDAQ: AWH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AWH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AWH stock methods without spending real money on the virtual paper trading platform.